“…It is noteworthy to mention that the first report of the gasdermin gene (now GSDMA) in the gastrointestinal tract (tightly restricted to the esophagus and stomach) and skin of a mouse was 2000 [ 220 ], and since then, many members of the gasdermin family have been reported; GSDMB, GSDMC, GSDMD, GSDME (also known as DFNA5) and PJVK (also known as DFNB59), with different activating enzymes both in human and mouse [ 221 , 222 , 223 ]. This expansive advancement in the understanding of the gasdermin family and its activating protease enzymes, such as inflammatory caspase 4/5/11 [ 112 , 221 ], non-inflammatory caspase 3/7/8 [ 222 , 223 ], Cathepsin G [ 224 ] and neutrophil elastase [ 225 ], as well as inflammasome activation [ 226 , 227 ], has further broadened the concept of cell death as critical therapeutic targets [ 228 , 229 ] in host immunity [ 230 , 231 ], microbial-induced hyperinflammation [ 140 , 232 ], cytokine storm syndrome [ 228 ] and autoimmune diseases [ 209 , 233 ], as well as in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [ 228 , 234 ]. Today, program cell deaths (PCD), particularly pyroptosis along with others, such as Necroptosis [ 235 ], Ferroptosis [ 236 ], NETosis [ 104 , 237 ], Parthanatos [ 238 ] and PANoptosis [ 133 , 135 ], have received a lot of attention from all facets of research disciplines.…”